Consequently, it is challenging for clinicians to decide to start anti-TB treatment in undetermined meningitis with elevated CSF-ADA, especially when meningitis patients in the areas with a high prevalence of TB show elevated CSF-ADA levels without any disease-specific symptoms or laboratory results. This evidence concerns the gene ADA and meningitis.